Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

IO Biotech, Inc. Common Stock · IOBTQ

IOBTQOTCCommon stockCurrentCIK 1865494Updated Oct 6, 2026

Company: IO Biotech, Inc. →

IOBTQ price & chart

Provider market data

Loading TradingView…

OTC:IOBTQ on TradingView ↗

TradingView · Data may be delayed

About the company

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).

8-K · 2026-01-30 · 0001193125-26-031987

Company description from the cited filing.

In the news

SEC disclosures

Recent filings

  1. 25-NSE - filed by Nasdaq Stock Market LLC regarding IO Biotech, Inc.

    25-NSE · 2026-06-08 · 0001354457-26-000541

  2. SCHEDULE 13D/A - filed by Lundbeckfond Invest A/S regarding IO Biotech, Inc.

    SCHEDULE 13D/A · 2026-06-02 · 0001591046-26-000008

  3. SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding IO Biotech, Inc.

    SCHEDULE 13G/A · 2026-05-15 · 0000919574-26-003515

  4. SCHEDULE 13G/A - filed by HBM Healthcare Investments (Cayman) Ltd. regarding IO Biotech, Inc.

    SCHEDULE 13G/A · 2026-04-06 · 0001104659-26-039923

  5. Bankruptcy or Receivership · Triggering Events That Accelerate or Increase a Direct Financial Obligation · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events

    Items 1.03, 2.04, 5.02, 8.01

    8-K · 2026-03-31 · 0001193125-26-133331

Show 5 more recent filings
  1. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    Items 3.01

    8-K · 2026-02-13 · 0001193125-26-051790

  2. SCHEDULE 13G - filed by Point72 Asset Management, L.P. regarding IO Biotech, Inc.

    SCHEDULE 13G · 2026-02-06 · 0000902664-26-000777

  3. Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events

    Items 2.05, 5.02, 8.01, 9.01

    8-K · 2026-01-30 · 0001193125-26-031987

  4. SCHEDULE 13D/A - filed by Novo Holdings A/S regarding IO Biotech, Inc.

    SCHEDULE 13D/A · 2026-01-23 · 0001388325-26-000003

  5. Other Events

    Items 8.01, 9.01

    8-K · 2026-01-21 · 0001193125-26-017164

Financials

FY 2024 · USD
Revenue— · FY 2024
Net income-95,491,000USD · FY 2024
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

Operating income-95,177,000USD · FY 2024
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

Diluted EPS-1.45USD per share · FY 2024
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ3 2025Q3 2024Q3 2023Q2 2025Q2 2024Q2 2023Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
ASSETS
AssetsUSD39,956,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

89,945,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

172,553,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

42,326,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

111,467,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

117,555,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

45,736,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

128,159,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

67,699,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

150,718,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

151,805,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

222,288,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Property, Plant and Equipment, NetUSD544,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

695,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

797,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

603,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

735,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

826,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

617,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

788,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

638,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

847,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

741,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

—
Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD30,664,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

80,185,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2024-09-30

165,501,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2023-09-30

28,131,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

100,747,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2024-06-30

110,095,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2023-06-30

37,086,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

117,982,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2024-03-31

60,031,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

143,193,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

142,590,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

211,531,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Assets, CurrentUSD36,831,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

86,244,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

168,254,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

38,980,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

107,652,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

113,036,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

42,342,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

124,128,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

64,951,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

147,255,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

148,219,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

221,738,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Prepaid Expense and Other Assets, CurrentUSD6,167,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

6,059,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

2,753,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

10,849,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

6,905,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

2,941,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

5,256,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

6,146,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

4,920,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

4,062,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

5,629,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

10,207,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Operating Lease, Right-of-Use AssetUSD1,302,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

1,814,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

2,367,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

1,470,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

1,936,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

2,534,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

1,585,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

2,092,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

1,725,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

2,259,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

2,493,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

—
Other Assets, NoncurrentUSD1,011,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

924,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

867,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

1,005,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

876,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

891,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

924,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

883,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

117,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

89,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

84,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

282,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD39,045,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

17,380,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

14,961,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

40,734,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

15,195,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

13,035,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

19,314,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

12,693,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

20,684,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

17,556,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

12,951,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

10,364,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD70,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

66,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

66,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

66,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

66,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

29,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

66,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

66,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

66,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

66,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

29,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

29,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Additional Paid in CapitalUSD424,335,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

411,479,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

405,039,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

416,289,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

409,797,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

330,217,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

414,682,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

408,154,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

413,113,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

406,587,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

326,705,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

319,665,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Retained Earnings (Accumulated Deficit)USD-416,329,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

-327,980,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

-237,640,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

-407,951,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

-303,965,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

-215,961,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

-381,734,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

-283,279,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

-359,313,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

-263,822,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

-177,739,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

-106,281,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Accumulated Other Comprehensive Income (Loss), Net of TaxUSD-7,165,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

-11,000,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

-9,873,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

-6,812,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

-9,626,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

-9,765,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

-6,592,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

-9,475,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

-6,851,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

-9,669,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

-10,141,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

-1,489,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Stockholders' Equity Attributable to ParentUSD911,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

72,565,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2024-09-30

157,592,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2023-09-30

1,592,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

96,272,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2024-06-30

104,520,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2023-06-30

26,422,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

115,466,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2024-03-31

47,015,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

133,162,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

138,854,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

211,924,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Liabilities and EquityUSD39,956,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

89,945,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

172,553,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

42,326,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

111,467,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

117,555,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

45,736,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

128,159,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

67,699,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

150,718,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

151,805,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

222,288,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Current liabilities:
Liabilities, CurrentUSD18,311,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

16,055,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

12,985,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

19,897,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

13,723,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

10,876,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

18,286,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

11,043,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

19,486,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

15,717,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

10,676,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

10,305,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Operating Lease, Liability, CurrentUSD788,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

694,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

627,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

768,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

678,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

613,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

735,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

666,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

717,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

655,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

515,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

—
Accounts Payable, CurrentUSD5,587,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

5,256,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

6,645,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

5,537,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

5,016,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

4,464,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

5,198,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

3,840,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

4,661,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

3,878,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

4,004,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

3,928,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Operating Lease, Liability, NoncurrentUSD667,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

1,325,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

As of 2024-09-30

1,976,000
Source

10-Q · 2023-11-13 · 0000950170-23-062963

As of 2023-09-30

868,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

1,472,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

As of 2024-06-30

2,159,000
Source

10-Q · 2023-08-11 · 0000950170-23-041620

As of 2023-06-30

1,028,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

1,650,000
Source

10-Q · 2024-05-14 · 0000950170-24-059108

As of 2024-03-31

1,198,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

1,839,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

As of 2023-12-31

2,275,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

As of 2022-12-31

—
Other Liabilities, NoncurrentUSD———————————59,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

As of 2021-12-31

Additional Financial Items
Long-term Debt, Current MaturitiesUSD——————0
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

—0
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

———
Long-term Debt, Excluding Current MaturitiesUSD16,664,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

As of 2025-09-30

——6,720,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

As of 2025-06-30

——0
Source

10-Q · 2025-05-14 · 0000950170-25-070956

As of 2025-03-31

—0
Source

10-K · 2025-03-31 · 0000950170-25-047744

As of 2024-12-31

———

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ4 2024Q4 2023Q3 2025Q3 2024Q2 2025Q2 2024Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD——————-22,421,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-19,457,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-95,491,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-86,083,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-71,458,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-67,879,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, Depletion and AmortizationUSD——100,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

100,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

100,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

100,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

100,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

100,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

300,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

200,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

100,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
Share-based Payment Arrangement, Noncash ExpenseUSD——————1,569,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

1,567,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

6,526,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

8,059,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

7,040,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

1,791,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts PayableUSD——————538,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-38,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

782,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-126,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

77,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

3,406,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Deferred Income Tax Expense (Benefit)USD——————————87,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-87,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD——————-23,071,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-24,932,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-82,347,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-71,737,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-59,729,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-40,646,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD——————-28,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-11,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-44,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-323,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-690,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-153,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Payments to Acquire Property, Plant, and EquipmentUSD——————28,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

11,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

44,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

323,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

690,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

153,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD——————0
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

0
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

—71,860,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

—252,951,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD——1,476,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

1,683,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

1,607,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

1,642,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

1,569,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

1,567,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

6,526,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

8,059,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

7,040,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

1,791,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

DepreciationUSD——————61,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

62,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

253,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

215,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

104,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
Foreign Currency Transaction Gain (Loss), before TaxUSD——98,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

1,630,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-374,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-90,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-105,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-462,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-3,589,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

331,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

130,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

319,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Foreign Currency Transaction Gain (Loss), RealizedUSD——————-105,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-462,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-3,589,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

331,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

130,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
General and Administrative ExpenseUSD——5,613,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

6,326,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

6,518,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

5,685,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

6,209,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

5,886,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

23,693,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

23,614,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

24,438,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

11,082,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Income Tax Expense (Benefit)USD——-1,664,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

209,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

118,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

374,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

146,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

415,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

1,443,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

852,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

1,273,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

68,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD——-8,378,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-24,015,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-26,217,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-20,686,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-22,421,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-19,457,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-95,491,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-86,083,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-71,458,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-67,879,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD——-8,378,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-24,015,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-26,217,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-20,686,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-22,421,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-19,457,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-95,491,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-86,083,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-71,458,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-74,987,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD——9,313,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

2,698,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-2,929,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

1,221,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

309,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

1,155,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

1,129,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

6,212,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

1,239,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-26,577,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Operating ExpensesUSD——19,355,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

26,504,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

23,170,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

21,533,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

22,584,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

20,197,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

95,177,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

91,443,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

71,424,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

41,234,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Operating Lease, ExpenseUSD——200,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

200,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

200,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

200,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

200,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

200,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

800,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

700,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

800,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

290,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Proceeds from Issuance of Common StockUSD———————————115,115,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Investment Income, Interest———
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

—
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

—
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

—
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

——————

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2024Q4 2023Q3 2025Q3 2024Q2 2025Q2 2024Q1 2025Q1 2024FY 2024FY 2023FY 2022FY 2021
Operating Income (Loss)USD——-19,355,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-26,504,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-23,170,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-21,533,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-22,584,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-20,197,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-95,177,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-91,443,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-71,424,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-41,234,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD——-10,042,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-23,806,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-26,099,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-20,312,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-22,275,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-19,042,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-94,048,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-85,231,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-70,185,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-67,811,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Income Tax Expense (Benefit)USD——-1,664,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

209,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

118,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

374,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

146,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

415,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

1,443,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

852,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

1,273,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

68,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Net Income (Loss) Attributable to ParentUSD——-8,378,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-24,015,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-26,217,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-20,686,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-22,421,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-19,457,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-95,491,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-86,083,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-71,458,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-67,879,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Earnings Per Share, BasicUSD per share——-0.13
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-0.36
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-0.4
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-0.31
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-0.34
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-0.3
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-1.45
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-1.98
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-2.48
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
Earnings Per Share, DilutedUSD per share——-0.13
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-0.36
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-0.4
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-0.31
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-0.34
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-0.3
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-1.45
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-1.98
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-2.48
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
Weighted Average Number of Shares Outstanding, Basicshares——66,941,964
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

65,880,914
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

65,880,914
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

65,880,914
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

65,880,914
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

65,880,914
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

65,880,914
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

43,539,976
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

28,815,267
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
Weighted Average Number of Shares Outstanding, Dilutedshares——66,941,964
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

65,880,914
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

65,880,914
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

65,880,914
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

65,880,914
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

65,880,914
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

65,880,914
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

43,539,976
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

28,815,267
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
Additional Financial Items
Current Income Tax Expense (Benefit)USD————————1,443,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

852,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

1,197,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

155,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Foreign Currency Transaction Gain (Loss), before TaxUSD——98,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

1,630,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-374,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-90,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-105,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-462,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-3,589,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

331,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

130,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

319,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Foreign Currency Transaction Gain (Loss), RealizedUSD——————-105,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-462,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-3,589,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

331,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

130,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
General and Administrative ExpenseUSD——5,613,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

6,326,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

6,518,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

5,685,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

6,209,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

5,886,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

23,693,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

23,614,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

24,438,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

11,082,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD————————1,977,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

2,365,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-1,885,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

206,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Interest ExpenseUSD——————————302,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

361,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Investment Income, NetUSD———1,068,000
Source

10-Q · 2024-11-12 · 0000950170-24-125524

2024-07-01 to 2024-09-30

—1,311,000
Source

10-Q · 2024-08-13 · 0000950170-24-096168

2024-04-01 to 2024-06-30

414,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

1,617,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

4,718,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

5,881,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

1,411,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

—
Net Income (Loss) Available to Common Stockholders, BasicUSD——-8,378,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

-24,015,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-26,217,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

-20,686,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

-22,421,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

-19,457,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

-95,491,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

-86,083,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

-71,458,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-74,987,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Nonoperating Income (Expense)USD——9,313,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

2,698,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

-2,929,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

1,221,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

309,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

1,155,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

1,129,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

6,212,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

1,239,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

-26,577,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Operating ExpensesUSD——19,355,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

26,504,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

23,170,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

21,533,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

22,584,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

20,197,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

95,177,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

91,443,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

71,424,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

41,234,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Operating Lease, ExpenseUSD——200,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

200,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

200,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

200,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

200,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

200,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

800,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

700,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

800,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

290,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Research and Development ExpenseUSD——13,742,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

20,178,000
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

16,652,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

15,848,000
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

16,375,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2025-01-01 to 2025-03-31

14,311,000
Source

10-Q · 2025-05-14 · 0000950170-25-070956

2024-01-01 to 2024-03-31

71,484,000
Source

10-K · 2025-03-31 · 0000950170-25-047744

2024-01-01 to 2024-12-31

67,829,000
Source

10-K · 2024-03-05 · 0000950170-24-026275

2023-01-01 to 2023-12-31

46,986,000
Source

10-K · 2023-03-14 · 0000950170-23-007902

2022-01-01 to 2022-12-31

30,152,000
Source

10-K · 2022-03-31 · 0000950170-22-005244

2021-01-01 to 2021-12-31

Investment Income, Interest———
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2025-07-01 to 2025-09-30

—
Source

10-Q · 2025-11-14 · 0001193125-25-281820

2024-07-01 to 2024-09-30

—
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2025-04-01 to 2025-06-30

—
Source

10-Q · 2025-08-14 · 0001193125-25-180860

2024-04-01 to 2024-06-30

——————

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

d13704dex991.htm · 8-K · 2026-01-30

Exhibit 99.1 IO Biotech Provides Corporate Update •  Raymond James engaged as financial advisor •  Reduction in force implemented New York, NY - January 30, 2026: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategi…

8-K · 2026-01-30 · 0001193125-26-031987

Read attachment ↗
d26457dex991.htm · 8-K · 2026-01-21

Exhibit 99.1 IO Biotech Announces Exploration of Strategic Alternatives New York, NY - January 21, 2026: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of asse…

8-K · 2026-01-21 · 0001193125-26-017164

Read attachment ↗
d59895dex991.htm · 8-K · 2025-11-18

EX-99.1 2 d59895dex991.htm EX-99.1 EX-99.1 Breaking Boundaries. Igniting Change. Nasdaq: IOBT Jefferies Healthcare Conference November 2025 Exhibit 99.1 DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business plan, clinical trials and regulatory submis…

8-K · 2025-11-18 · 0001193125-25-285282

Read attachment ↗
d36523dex991.htm · 8-K · 2025-11-14

EX-99.1 2 d36523dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical significance on the PFS primary endpoint was narrowly missed Meeting scheduled with FDA in December to align on the design of …

8-K · 2025-11-14 · 0001193125-25-281657

Read attachment ↗
d940102dex991.htm · 8-K · 2025-09-29

EX-99.1 2 d940102dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Provides Update Following Pre-BLA Meeting with FDA FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced melanoma Company implementing a restructuring, reducing its workforce by approximately 50 percent ──────────────────…

8-K · 2025-09-29 · 0001193125-25-221704

Read attachment ↗
d34608dex991.htm · 8-K · 2025-08-14

EX-99.1 2 d34608dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet with FDA this fall to discuss data and next steps for a potential regulatory submiss…

8-K · 2025-08-14 · 0001193125-25-180830

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.